Dennis Liotta


Professor Dennis Liotta has helped transform HIV/AIDS from a death sentence to a chronic infection in which patients are able to live active, near normal lives.  More than 90 percent of all of the HIV-infected persons in the United States take (or have taken) one of the drugs he invented.

In his current role as the Executive Director of the Emory Institute for Drug Development, he oversaw the discovery and development of another novel drug for treating hepatitis C infections, and his research group has recently discovered the first potent, dual tropic (CCR5/CXCR4) HIV entry inhibitors. Over the past two and a half decades Liotta’s research has focused on the discovery and development of novel antiviral, anticancer and anti-­inflammatory therapeutic agents.

He is also the lead inventor of Q-­122, a safe, orally available clinical agent for controlling hot flashes in post-­menopausal women.

Mr. Liotta is a prolific user of the patent system and a supporter of WIPO Re:Search, which uses innovative research partnerships and knowledge sharing to catalyze development of medical products for neglected tropical diseases, malaria, and tuberculosis.


You are here